FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
about
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentCIViC databaseThe consequences of Rad51 overexpression for normal and tumor cellsITD assembler: an algorithm for internal tandem duplication discovery from short-read sequencing data.STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative diseasePatterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaA chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translationPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsMolecular mechanisms of drug resistance in acute myeloid leukaemia.Clinical relevance of the homologous recombination machinery in cancer therapy.FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.Targeting FLT3 to treat leukemia.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
P2860
Q27027207-5A7EEDDB-A74A-45A1-8316-BFD532D8368FQ27612411-30C6610A-8CD1-431A-9CA0-FEC6A7FA8FA7Q28266986-BDFEE1CC-BE79-47E6-A23A-DE9B653D0C1EQ31086279-883D8E8F-785C-4D8F-99A0-48C005C25206Q33680286-6FBE3BC2-08F8-4B45-9EB7-FC61C26C9D83Q33913329-FB2D1521-96E4-435F-A915-0564FE6C1011Q33934987-9AAAB4FC-D5F1-4176-A394-B51FFB6E188EQ34095013-3C7AE7BB-DCA0-4B8E-817B-3DD66DD804B3Q34309928-B285DBA7-273A-417C-ACD2-7CA8537D5BC7Q34360637-A13995D0-1007-44F8-AE99-6CC950729CB2Q34709391-1FC3D15B-2167-4FBA-A0A4-556D73F73D95Q34754412-7D374EAF-7835-43D6-BF97-BD3354F05401Q36390379-A0754A25-64DB-40B7-A843-5CA2EEA55BEEQ36400942-2421B033-C1DB-4A04-9892-A8E190CC5D70Q36835812-9F37A0D6-26B6-44F7-B8C3-298C822755EDQ36978266-B2D83F5A-DD9F-4C07-9250-085E3EE62AF1Q38026453-10ACB0A4-A786-4C42-B2AB-7F75E796AF40Q38168893-BCB8E7C3-751A-4B00-BF5D-7DBDE94F2454Q38238954-0014A7F1-DEAA-4CC9-B3C4-5ACC83100036Q38251339-DA268BC1-4F2C-4AE9-A231-2BED94B7DBC7Q38428692-D69A3702-A7B5-4D2F-8B66-ACFD65B20E4BQ38675400-B39EED59-F660-49DE-A920-37BE94189D4CQ39411949-C121C805-578A-4B40-9E22-3B0DE984084AQ40215417-CA25C9A2-2E02-4365-9225-35B51429A131Q40218888-5A0DE101-3D11-4C8B-9800-78BFC9F61E83Q46549470-B7099121-1187-471A-A551-BDB64D44365DQ47965108-02ACCB50-01AA-4879-8119-C817D854C5D8Q50514234-D4CCBBD1-79A1-4C3D-99CB-F662F2856492Q54596100-9AAC4A7C-BB20-4FA4-9E0C-B53080544F41Q58739975-F5679FFB-6350-4C77-B8B5-5DB35422032A
P2860
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@ast
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@en
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@nl
type
label
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@ast
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@en
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@nl
prefLabel
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@ast
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@en
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@nl
P2093
P3181
P1433
P1476
FLT3-ITD-TKD dual mutants asso ...... by overexpression of Bcl-x(L).
@en
P2093
Carola Reindl
Joachim W Ellwart
Karsten Spiekermann
Ksenia Bagrintseva
Sabine Eichenlaub
Stefanie Geisenhof
Wolfgang Hiddemann
P304
P3181
P356
10.1182/BLOOD-2004-06-2459
P407
P577
2005-05-01T00:00:00Z